Genenta Science (NASDAQ:GNTA) Trading Down 3.1% – What’s Next?

Shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) fell 3.1% on Monday . The stock traded as low as $1.2350 and last traded at $1.26. 59,577 shares were traded during mid-day trading, an increase of 3% from the average session volume of 58,073 shares. The stock had previously closed at $1.30.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Genenta Science from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Genenta Science currently has an average rating of “Sell”.

Genenta Science Trading Down 3.1%

The stock has a 50 day moving average of $1.58 and a 200 day moving average of $1.11. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.16 and a quick ratio of 14.16.

Hedge Funds Weigh In On Genenta Science

Several institutional investors have recently modified their holdings of GNTA. Citadel Advisors LLC bought a new position in Genenta Science during the third quarter valued at approximately $41,000. SmartHarvest Portfolios LLC purchased a new position in shares of Genenta Science during the fourth quarter worth approximately $26,000. Alyeska Investment Group L.P. bought a new stake in shares of Genenta Science in the 4th quarter worth approximately $328,000. Norges Bank bought a new stake in shares of Genenta Science in the 4th quarter worth approximately $337,000. Finally, Weiss Asset Management LP purchased a new stake in shares of Genenta Science in the 4th quarter valued at $480,000. 15.13% of the stock is currently owned by institutional investors.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.